SyMRI to be studied as a technology to characterize brain tumors

SyntheticMR and The University of Texas MD Anderson Cancer Center have signed a research agreement to study SyMRI to characterize brain tumors.

Photo: SyMRI to be studied as a technology to characterize brain tumors

SyMRI provides quantitative information including tissue segmentation and T1, T2 and PD-maps, thus adding objective data to the MRI exam. The technology will be studied for its potential to add diagnostic value for various clinical applications including characterization of brain tumors.

SyMRI IMAGE generates multiple contrast images from a single 3 to 6 minutes scan, thus allowing a significant reduction in scan time compared to serial acquisition of each contrast image separately. Parameters are also adjustable post scan, enabling both fine tuning of images as well as recreation of additional contrasts.  SyMRI NEURO adds quantitative data and automatic segmentation of brain tissue for efficient analysis and objective decision making. The agreement with MD Anderson includes a license of SyMRI IMAGE and SyMRI NEURO for research use at the hospital. SyMRI is CE-marked for clinical use in Europe but SyMRI is not available for clinical use in the USA.

Source: SyMRI


Read all latest stories

Related articles


Brain tumor treatment network

'Federated learning' AI approach allows hospitals to share patient data privately

To answer medical questions that can be applied to a wide patient population, machine learning models rely on large, diverse datasets from a variety of institutions. However, health systems and…



New insights into deadly brain tumours in children

The causes of 40 percent of all cases of certain medulloblastoma – dangerous brain tumors affecting children – are hereditary. These are the findings of a recent genetic analysis carried out by…


MRI & machine learning

A look into the genome of brain tumors

Researchers at Osaka University have developed a computer method that uses magnetic resonance imaging (MRI) and machine learning to rapidly forecast genetic mutations in glioma tumors, which occur in…

Related products

Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH